Oncology On The Go

Yancey Warren, Jr, MD, MAT, a breast surgery oncology fellow at Brown University, and Lejla Hadzikadic-Gusic, MD, MSc, associate professor of surgery, Division of Surgical Oncology at Atrium Health Levine Cancer Institute, spoke with CancerNetwork® about their study titled Integrative Oncology in Young Women with Breast Cancer, which was published in the journal ONCOLOGY®.In their study, the authors explored the potential benefit of integrative oncology strategies to better establish referral practices for Levine Cancer Institute and define optimal timing for treatment in young patients with breast cancer. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts,Spotify, or anywhere podcasts are available.

During the 2022 San Antonio Breast Cancer Symposium (SABCS), CancerNetwork® spoke with several multidisciplinary oncology experts from the Mayo Clinic in Rochester, Minnesota about their respective key takeaways from the presentations on developments in the breast cancer space, including surgery, radiotherapy, and biomarker research. Judy C. Boughey, a surgical oncologist of the Division of Breast and Melanoma Surgical Oncology and the Department of Surgery, discussed her research on the impact of breast conservation therapy on local recurrence rates in multiple ipsilateral breast cancer in the phase 2 ACOSOG Z11102 (Alliance) trial (NCT01556243). Robert Mutter, MD, an associate professor of the Department of Radiation Oncology, spoke about his work on a randomized phase 2 trial assessing the use of conventional vs hypofractionated proton radiotherapy following a mastectomy among patients with breast cancer. Siddhartha Yadav, MD, MBBS, a medical oncologist and assistant professor of Medicine and Oncology, highlighted data from the population-based CARRIERS study, assessing germline pathogenic variants and other factors as risks for contralateral breast cancer. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts,Spotify, or anywhere podcasts are available.

Ibrahim Halil Sahin, MD, a medical oncologist specializing in gastrointestinal oncology and an assistant professor at the University of Pittsburgh Medical Center, Hillman Cancer Center, spoke with CancerNetwork® about his manuscript titled Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US, which was recently published in the journal ONCOLOGY®. In the article, Sahin and his colleagues explored postoperative circulating tumor DNA dynamics in early-stage colon cancer and investigated escalation and de-escalation approaches using ctDNA status as a surrogate for minimal residual disease status. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

As part of the Between the Lines™ video series, Bruce Cheson, MD, FACP, FAAAS, FASCO, a board certified hematologist at the Center for Cancer and Blood Disorders in Bethesda, Maryland, spoke with Steven Park, MD, an oncologist and vice chair of Research at the Atrium Health Levine Cancer Institute and a clinical professor of Medicine at Wake Forest University. These experts shared their insight on the phase 1/2 E7438-G000-101 (NCT01897571) clinical trial and highlighted key data on tazemetostat (Tazverik), an EZH2 inhibitor, in relapsed or refractory follicular lymphoma. In the video series, Cheson and Park discussed the following: · Overview of relapsed/refractory follicular lymphoma and available treatment options · Tazemetostat trial data and propensity score-matched analysis · Role of tazemetostat treatment moving forward Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Daniel C. McFarland, DO, and Dr. Kirk Harris, MD, both of the University of Rochester, spoke with CancerNetwork® about their manuscript titled, “Cancer Pain and Opioid Use Disorder,” which was recently published in the journal ONCOLOGY®. In the review, the authors explore current approaches for screening of opioid use disorder, evaluation of psychosocial stressors, factors that qualify the disorder, and management of patients suffering with addiction. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Coauthors Dori Beeler, PhD, of the Levine Cancer Institute; Shelley Wang, MD, MPH, of The University of Texas MD Anderson Cancer Center; and Viraj A. Master, MD, PhD, of the Winship Cancer Institute of Emory University, spoke with CancerNetwork® about their review published in the journal ONCOLOGY® titled Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research Recommendations. In the article, the authors and their colleagues explored negative impacts, mechanisms, and measurement concerns surrounding cancer-related fatigue. They also proposed strategies for standardization and future directions in the space.

Robert Stuver, MD, and Zachary D. Epstein-Peterson, MD, spoke with CancerNetwork® about a review article on the treatment of peripheral T-cell lymphoma published in the journal ONCOLOGY®.

Juan Pablo Alderuccio, MD, assistant professor of medicine in the Division of Hematology, Department of Medicine at the Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine in Florida, spoke with CancerNetwork® about his review published in the journal ONCOLOGY® titled, Current Treatments in Marginal Zone Lymphoma. In the article, Alderuccio explored current approaches to the diagnosis and treatment of marginal zone lymphoma. He also touched on his strategies for treating localized versus advanced disease and novel emerging strategies clinicians practicing in the community should be aware of. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Kira MacDougall, MD, a first year fellow at the University of Oklahoma, and Muhammad Rafay Khan Niazi, MD, a third year resident of Internal Medicine at Staten Island University Hospital, spoke with CancerNetwork® about research published in the journal ONCOLOGY® titled, The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab: A Clinical Study.MacDougall and Niazi discuss the clinical utility of absolute lymphocyte count (ALC) and the ratio of absolute neutrophil count to ALC for predicting outcomes with pembrolizumab (Keytruda) in advanced non–small cell lung cancer. They also talked about future research in the space and what unanswered questions remain in this treatment setting.Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Kirk E. Cahill, MD, and Sonali M. Smith, MD, both of the Department of Medicine, Section of Hematology/Oncology at the University of Chicago Medicine Comprehensive Cancer Center in Chicago, Illinois, spoke about their manuscript titled, ‘Follicular Lymphoma: a Focus on Current and Emerging Therapies,’ that was recently published in the journal ONCOLOGY®. In the review, the authors explore current approaches to the diagnosis and treatment of follicular lymphoma, with a focus on emerging investigational therapies and novel combination strategies. Some areas of unmet need they touch on in the paper include precision approaches to individual patients, trial end points with quality-of-life measures, and guidance for sequencing of available regimens and agents. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

In the inaugural Twitter Spaces edition of the Oncology Peer Review On-The-Go podcast hosted by CancerNetwork®, Paolo Tarantino, MD, a clinical research fellow at Dana-Farber Cancer Institute, and Sara M. Tolaney, MD, MPH, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancer at Dana-Farber as well as an associate professor of medicine at Harvard Medical School, reviewed presentations in breast cancer research from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. During the live event, Tarantino and Tolaney discussed the phase 3 DESTINY-Breast04 trial (NCT03734029), of fam-trastuzumab-nxki (Enhertu) vs chemotherapy for patients with HER2-low, hormone receptor–positive metastatic breast cancer. The co-hosts also reviewed surprising results from phase 3 PALOMA-2 trial (NCT01740427), which failed to show an overall survival benefit with use of palbociclib (Ibrance) plus letrozole in patients with estrogen receptor–positive/HER2-negative advanced breast cancer vs letrozole alone. Additionally, Tolaney discussed her presentation of the phase 3 monarchE trial (NCT03155997) that explored adjuvant abemaciclib (Verzenio) in patients with hormone receptor–positive, HER2-negative, node-positive high-risk early breast cancer. Overall, both investigators said they enjoyed coming back to in-person conferences and how they hope the trend of practice-changing trials continues with future conferences. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Suneel D. Kamath, MD, of the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, spoke with the editorial team of the journal ONCOLOGY® about his published manuscript titled, ‘Association of Financial Conflicts of Interest With Academic Productivity Among Junior Faculty in Hematology and Oncology.’ Suneel and colleagues set out to determine how financial conflicts of interest could be used as a surrogate for the trajectory of early-career oncologists and junior faculty at academic institutions. He touched on how understanding relationships between clinicians and industry is important for both drug development as well as the early academic productivity of individual investigators. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Nora Janjan, MD, MPSA, MBA, who sits on the editorial advisory board for the journal ONCOLOGY®, spoke about her perspective titled, ‘Academic Promotion and Oncology Drug Development: Role, Responsibilities, and Integrity.’ In the article, Janjan explores the role conflicts of interests (COIs) play in research integrity and how individual investigators are upholding their end of the deal by practicing safe reporting of relationships with the industry. Her narrative complements a cross-sectional study of junior faculty at major academic cancer centers to evaluate patterns of COIs with years of clinician experience to determine if increasing COIs and industry funding correlate with greater academic success. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

This week, CancerNetwork® spoke with Judd W. Moul, MD, editorial board member for the journal ONCOLOGY® and James H. Semans, MD, Distinguished Professor of Urologic Surgery at Duke University School of Medicine, leads a discussion with medical student Kostantinos E. Morris, from Duke University School of Medicine, on research recently published in the journal ONCOLOGY®titled, ‘Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs.’ The manuscript was based on the case of a patient who presented to their clinic with elevated prostate-specific antigen (PSA) levels and multiple imaging tests that appeared to indicate an absence of malignancy. Their discussion includes why they continued to investigate the cause of the elevated PSA levels, how they overcame the patient’s hesitation for more testing, and the ultimate outcome of the case.Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.As part of its Between the Lines™ video series, CancerNetwork® spoke with Paul G. Richardson, MD, clinical program leader and director of Clinical Research for the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in Boston, Massachusetts, and Christina Gasparetto, MD, professor of medicine at Duke University Medical School in Durham, North Carolina, about recent updates in the use of proteasome inhibitors for patients with multiple myeloma.In the video series, Richardson and Gasparetto discussed the following:· Overview of proteasome inhibitor therapy in multiple myeloma · Real-world data with proteasome inhibitors · The phase 3 TOURMALINE-MM1 trial (NCT01564537) of ixazomib therapy in relapsed/refractory multiple myeloma · Ixazomib plus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma Be sure to tune in to other videos in the CancerNetwork® Between the Lines™ series.

This week, CancerNetwork turns to the second part of its 3-part series focused on colorectal cancer. Tanios Bekaii-Saab, MD, a gastrointestinal cancers (GI) medical oncologist at the Mayo Clinic Cancer Center, continues the conversation with Kristen Ciombor, MD, MSCI, a GI medical oncologist and associate professor of medicine at Vanderbilt-Ingram Cancer Center, and John Strickler, MD, a GI medical oncologist, associate professor of medicine, and co-leader of the Molecular Tumor Board at Duke University School of Medicine.This episode’s discussion turns to the GOZILA platform and its international collaboration. The experts expand on this platform, what it means for drug development, and examine genetic testing in GI malignancies.Tune in next week for the third and final part of this conversation on colorectal cancer.Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork looks at the final part of its 3-part series focused on colorectal cancer. Tanios Bekaii-Saab, MD, a gastrointestinal cancers (GI) medical oncologist at the Mayo Clinic Cancer Center, concludes his conversation with Kristen Ciombor, MD, MSCI, a GI medical oncologist and associate professor of medicine at Vanderbilt-Ingram Cancer Center, and John Strickler, MD, a GI medical oncologist, associate professor of medicine, and co-leader of the Molecular Tumor Board at Duke University School of Medicine.This conversation focuses on resistance to targeted therapies in metastatic colorectal cancer, and the importance of addressing it. The experts also discuss EGFR resistance, EGFR rechallenging after prior progression, and rising HER2 amplification.Thanks for tuning in to this series on colorectal cancer from CancerNetwork. Visit cancernetwork.com to catch up on any episodes you missed and to read more about these topics published in the journal ONCOLOGY.Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork kicks off the first of a 3-part podcast series focused on colorectal cancer. Tanios Bekaii-Saab, MD, a gastrointestinal cancers (GI) medical oncologist at the Mayo Clinic Cancer Center, leads a conversation with Kristen Ciombor, MD, MSCI, a GI medical oncologist and associate professor of medicine at Vanderbilt-Ingram Cancer Center, and John Strickler, MD, a GI medical oncologist, associate professor of medicine, and co-leader of the Molecular Tumor Board at Duke University School of Medicine.This conversation focuses on the current molecular treatment landscape of advanced colorectal cancer and the need for the COLOMATE platform. Among other things, the experts detail this platform and expand on its impact for patients, as well as the evolving world of colorectal cancer.Make sure to tune in next week for part 2 of this conversation on colorectal cancer.Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

As part of its OncView™ program, CancerNetwork hosted a discussion Lori Wirth, MD, associate professor of medicine at Harvard Medical School and medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital in Boston, who shared her perspective on updates in the treatment of second-line radioiodine-refractory differentiated thyroid cancer, or DTC.In the video series, some of the content discussed included:· Presentation and Disease Course of Differentiated Thyroid Cancer · Frontline Treatment Options for RAI-refractory DTC · Treatment Options in RAI-refractory DTC in Second Line and Beyond · Facing Unmet Needs and Ongoing Trials in RR-DTC To watch more videos in the CancerNetwork® OncView™ series, visit cancernetwork.com/oncview. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

As part of its OncView™ video series, CancerNetwork® spoke with David H. Aggen, MD, PhD, of the Memorial Sloan Kettering Cancer Center, Robert S. Alter, MD, of the John Theurer Cancer Center, Arnab Basu, MD, MPH, of the O’Neal Comprehensive Cancer Center, Mehmet Asim Bilen, MD, of Winship Cancer Institute, and Chung-Han Lee, MD, MPH, of Memorial Sloan Kettering Cancer Center, who shared their thoughts on recent advances in treatment options for metastatic renal cell carcinoma (RCC) and commented on emerging data in the field. To watch more videos in the CancerNetwork® OncView™ series, visit cancernetwork.com/oncview. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

OncView™ Podcast: Mobocertinib Use in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive mNSCLC As part of its OncView™ video series, CancerNetwork® spoke with Gregory Riely, MD, PhD, vice chair of Clinical Research in the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York, and Tarek Mekhail, MD, a hematologic oncologist from Advent Health in Florida, about patients with EGFR exon 20 insertion-positive metastatic non–small cell lung cancer who recieved mobocertinib. In the video series, Gregory Riely, MD, PhD, and Tarek Mekhail, MD, discussed the following: Mobocertinib Use in mNSCLC: EXCLAIM Cohort Study Design Efficacy Data From the EXCLAIM Cohort in mNSCLC EXCLAIM Cohort: Mobocertinib Safety Data in mNSCLC EXCLAIM Cohort in mNSCLC: Treatment Selection and Management mNSCLC: Biomarker Testing and Patient Adherence to TKIs Next Steps in the Management of EGFR Exon 20 Insertion–Positive mNSCLC To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.

This week, CancerNetwork® spoke with Christine Chung, DO, of the Swedish Medical Center, Englewood, Colorado, about “Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma,” a retrospective review published in the journal ONCOLOGY. Chung detailed this research, which characterizes the mutational landscape of patients with metastatic pancreatic adenocarcinoma who received blood-based molecular profiling. A total of 77 consecutive patients were included in the analysis. Chung also spoke about pancreatic adenocarcinoma, the study’s main findings, and how this research can inform future treatment decision-making processes moving forward. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork® spoke with Muhammad Niazi, MD, resident in internal medicine at Staten Island University Hospital, and Alexander Bershadskiy, MD, attending physician at Staten Island University Hospital, about a meta-analysis published in ONCOLOGY titled, “Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.” The final analysis evaluated 3 randomized clinical trials. A fixed model showed a statistically significant improvement in overall survival for patients with metastatic castration-resistant prostate cancer treated with PARP inhibitors. The authors provided a detailed background on PARP inhibitors and further detailed the results of this research, focusing on survival increases with PARP inhibitor treatment for this patient population. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

As part of its OncView™ video series, CancerNetwork® spoke with Zofia Piotrowska, MD, an assistant professor of medicine at Harvard Medical School and a lung cancer medical oncologist at Massachusetts General Hospital, about recent data and review updates in the treatment landscape for patients with non-small-cell lung cancer and exon 20 insertions.In the video series, Piotrowska discussed the following:· Overview of Advanced NSCLC with EGFR Mutations Including Exon 20 Insertions · Testing for the EGFR Exon 20 Insertion · Historical Treatment Approach for EGFR Exon 20 Insertions in NSCLC · Amivantamab for the Treatment of EGFR Exon 20 Insertions in NSCLC · Mobocertinib for the Treatment of EGFR Exon 20 Insertions in NSCLC · Treatment Selection for Patients With EGFR Exon 20 Insertions in NSCLC · Unmet Needs and Future Directions To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

As part of its Between the Lines™ video series, CancerNetwork® spoke with Liliana Bustamante, MD, hematologist and medical oncologist at Florida Cancer Specialists in Fort Myers, Florida and Richard Kim, MD, service chief of Medical Gastrointestinal Oncology and senior member in the Gastrointestinal Oncology Department at the Moffitt Cancer Center in Tampa, Florida, about the prognostic potential of circulating tumor DNA (ctDNA) as a biomarker for patients with oligometastatic colorectal cancer.In the video series, Bustamante and Kim discussed the following:· Presentation: ctDNA Assays For Patients With CRC Undergoing Resection of Metastases · Key Takeaways: ctDNA Assays For Patients With CRC Undergoing Resection of Metastases · ctDNA as a Biomarker in CRC · ctDNA Assays in CRC: Interpreting Clinical Findings · ctDNA Assays in CRC: Impact on Clinical Practice · Next Steps in Using ctDNA as a Biomarker in CRC · Recap: Prognostic Potential of ctDNA for Oligometastatic Colorectal Cancer To watch more videos in CancerNetwork®’s Between the Lines™ series, visit cancernetwork.com/between-the-lines.Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

As part of its OncView™ video series, CancerNetwork® spoke with John Kirkwood, MD, PhD, director of the melanoma center at the University of Pittsburgh Medical Center Hillman Cancer Center, about using immunotherapy for treating melanoma and how to monitor responses in patients properly. In the video series, Kirkwood discussed the following: · Treatment Options for Melanoma · Considerations for Immunotherapy Use When Treating Melanoma · Monitoring Responses to Melanoma Therapy · Pseudoprogression in Melanoma Therapy · ctDNA for Melanoma Treatment Monitoring · Using ctDNA to Monitor Patients With Melanoma · Taking Drug Holidays Amidst Melanoma Therapy · Duration of Treatment for Melanoma To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

As part of its OncView™ video series, CancerNetwork® spoke with Roy Herbst, MD, PhD, chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, about currently available treatment options and strategies in immunotherapy for treating non–small cell lung cancer (NSCLC). In the video series, Herbst discussed the following: · Treatment Options in Non–Small Cell Lung Cancer · Monitoring Response to Therapy in NSCLC · Role of ctDNA in Monitoring Treatment Response in NSCLC · Clinical Decision-Making in NSCLC · Recap: Monitoring With ctDNA for Immunotherapy Response in Lung Cancer To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork spoke with Matthew Matasar, MD, a lymphoma specialist and chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center Bergen, about research from the December issue of ONCOLOGY titled, “Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab.” The retrospective, observational analysis examined patient care delivery and practice efficiency changes using real-world data. Patients with diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia who received a rituximab-containing regimen were eligible for the study. Matasar touched on subcutaneous rituximab, the role it can play in treatment, the time savings associated with its use, and more. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

CancerNetwork spoke with Jun Gong, MD, a practicing medical oncologist who specializes in the treatment of genitourinary cancers at Cedars-Sinai Medical Center, regarding a perspective piece titled, “Cisplatin Neoadjuvant Chemotherapy in an Aging Population With Muscle-Invasive Bladder Cancer.”Gong’s perspective focuses on an article published in the January issue of ONCOLOGY titled, “Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017.”In this conversation, Gong overviewed the research and touched on some of the clinically relevant findings. He then detailed his perspective and expanded on cisplatin-based chemotherapy, how age fits into the treatment equation, and where research should focus moving forward in muscle-invasive bladder cancer.Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

CancerNetwork® recently spoke with Ofer Sharon, MD, CEO of OncoHost, about interim results from the prospective PROPHETIC trial to predict how patients with non–small cell lung cancer respond to immunotherapy. Sharon first described OncoHost and the mission of this clinical stage precision oncology company. Then, he touched on the key details of this research, with a focus on the PROphet diagnostic platform at the center of this ongoing multicenter clinical trial, as well as what comes next for this research and OncoHost. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

CancerNetwork® spoke with Emily Smith, MD, of the Ellis Fishchel Cancer Center, University of Missouri, about a patient case published in the December issue of the journal ONCOLOGY titled, “Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous Carcinosarcoma.” Smith and colleagues detailed a case regarding a 56-year-old man who the team of care providers diagnosed with metastatic basal cell carcinoma arising from a carcinosarcoma. In the conversation, Smith talked about what makes this patient case unique, the timeline of this specific patient’s disease and treatment, the rarity of basal cell carcinoma arising from a carcinosarcoma, and plenty more. Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

CancerNetwork spoke with Matthew Allaway, DO, founder and CEO of Perineologic, about a new prostate cancer biopsy technique that uses the transperineal approach to detect cancer in harder to reach areas of the prostate.Allaway touched on the American Cancer Society’s annual report that shows the rate of advanced-stage prostate cancer cases are increasing in recent years. He also detailed a companion study to that report, and walked through the specific details and benefits of this biopsy technique.Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork closed the book on the year that was 2021. CancerNetwork spoke with Amy Comander, MD, co-medical director and director of breast oncology and cancer survivorship at Mass General Cancer Center, about some of the key developments and data to emerge from 2021 for patients with breast cancer, with a specific focus on the 2021 San Antonio Breast Cancer Symposium (SABCS).Not only did Comander detail important information from 2021 in the field of breast cancer, but she also touched on how the field is continuously evolving and shared her thoughts on what’s in store for patients in 2022.Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

As part of its Between the Lines™ video series, CancerNetwork® spoke with Lyudmila Bazhenova, MD, a professor of medicine at the University of California San Diego Health, and Federico Albrecht, MD, an oncologist/hematologist at Miami Cancer Institute, Baptist Health South Florida, about when and how to use real-world evidence when making treatment decisions for patients with EGFR-mutated non–small cell lung cancer (NSCLC).In the video series, Bazhenova and Albrecht discussed the following:· Presentation: Benefits and Limitations of RWE: Lessons From EGFR Mutation-Positive NSCLC · EGFR-Mutant NSCLC: Addressing Gaps When Collecting Data · Experts in Treating EGFR-Positive NSCLC Compare Randomized Trials and Real-World Studies · EGFR-Mutant NSCLC: Incorporating RWE Into Treatment Decisions · Referring to Real-World Evidence When Managing EGFR-Mutant NSCLC · Using Various Sources of Information to Guide Management of EGFR-Mutated NSCLC · Increasing Rates of Real-World Studies in EGFR-Mutated NSCLC To watch more videos in CancerNetwork®’s Between the Lines™ series, visit cancernetwork.com/between-the-lines.Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork spoke with Don Dizon, MD, about certain unique challenges LGBTQ+ patients face when navigating through their cancer journey, and how providers can improve these experiences. The director of women’s cancers at the Lifespan Cancer Institute, director of medical oncology at Rhode Island Hospital, and professor of medicine at the Warren Alpert Medical School of Brown University in Providence, touched on overcoming barriers in clinical cancer research, creating a gender-affirming environment for patients, and other important topics for treating LGBTQ+ patients with cancer.Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

The final episode of CancerNetwork’s 4-part series on small cell lung cancer (SCLC) welcomes back Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. In this conversation, Iams looks to the future of SCLC treatments, touching on topics including extending response durations for patients, emerging therapies for extensive stage SCLC, exciting research on the horizon, and more.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.Check out the previous podcast episodes in this series:· Episode 1: First-Line Therapeutic Options in Small Cell Lung Cancer · Episode 2: Treatment Options for Relapsed/Refractory Small Cell Lung Cancer · Episode 3: Practical Considerations for Small Cell Lung Cancer Therapeutic Options

Jun Gong, MD, discussed his perspective piece from the October issue of the journal ONCOLOGY, titled “An Evolving Relationship Between Medical Oncologists and Genetic Counselors in Prostate Cancer.” Gong, a practicing medical oncologist who specializes in the treatment of genitourinary cancers at Cedars-Sinai Medical Center, commented on a review article previously examined on this podcast with Alexandra Sokolova, MD, titled “Germline Testing in Prostate Cancer: When and Who to Test.”The review article focuses on the treatment implications of germline testing and how this type of testing is becoming more commonplace. Gong’s perspective applauds Sokolova and her colleagues for their work and expands on the necessary relationship between medical oncologists and genetic counselors to effectively treat patients with prostate cancer.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

In the third part of a 4-part series on small cell lung cancer (SCLC), CancerNetwork spoke with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. The conversation focused on the toxicities of treatment options, quality of life for patients, and how Iams suggests managing and mitigating those events for individuals with SCLC. Some of the agents and regimens discussed include lurbinectedin and trilaciclib, as well as chemotherapy and immunotherapy.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.Check out the previous podcast episodes in this series:· Episode 1: First-Line Therapeutic Options in Small Cell Lung Cancer · Episode 2: Treatment Options for Relapsed/Refractory Small Cell Lung Cancer

This week’s conversation focuses on TrialJectory, a digital health company that utilizes artificial intelligence to inform patients with cancer on their treatment journey. CancerNetwork spoke with Tzvia Bader, CEO and co-founder of TrialJectory, and Karine Perreault, who recently was diagnosed with breast cancer and is on the TrialJectory platform. The conversation touches on the perceived disconnect between the pharmaceutical industry and patients, the need to remove barriers to access testing, and the action items they thinks need to be prioritized to improve access for women with cancer.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

In the second part of a 4-part series on small cell lung cancer, CancerNetwork continued its conversation with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. Iams turned the attention to different treatment options for patients with relapsed/refractory small cell lung cancer. Among others, Iams touched on lurbinectedin, topotecan, and some of the crucial clinical trials associated with treatment options for small cell lung cancer, including a phase 2 basket trial and phase 3 ATLANTIS trial examining lurbinectedin.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.Check out the first episode of this series on first-line therapeutic options in small cell lung cancer.

CancerNetwork looks at research from the October issue of the journal ONCOLOGY, titled “Value of Geriatric Assessment in Patients With Genitourinary Carcinoma.” Lead author, Quirin Zangl, MD, from the Department of Neuroanesthesia, at the Christian Doppler Hospital in Salzburg, Austria, spoke in detail about the manuscript.The research featured 111 patients with urogenital carcinomas with the goal of evaluating comprehensive geriatric assessment tools to better guide these individuals. Patients were divided into 2 groups, which were prostate cancer (n = 88) and distal urinary tract cancer (n = 29). Overall, the relationships between comprehensive geriatric assessment tools and complications, hospital duration, death rate, and baseline characteristics were analyzed.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork looks at an article from the October issue of the journal ONCOLOGY, titled “Germline Testing in Prostate Cancer: When and Who to Test.” CancerNetwork spoke with one of the authors of this article, Alexandra Sokolova, MD, an assistant professor at Oregon Health & Science University. Sokolova detailed the article, which summarizes germline testing recommendations for prostate cancer, specifically looking at the recently updated NCCN guidelines, as well as describing care models for providing counsel and testing for patients. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

In this special episode of the "Oncology Peer Review On-The-Go" podcast, CancerNetwork spoke with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center, about therapeutic advances for small cell lung cancer. Iams discussed the current first-line therapies for small cell lung cancer, the IMpower133 and CASPIAN trials, and the factors considered for treating patients in the first-line setting. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

As part of its OncView video series, CancerNetwork spoke with Connie Batlevi, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, about recent updates in therapies for relapsed or refractory follicular lymphoma. Batlevi discussed the current treatment options for this disease, as well as third-line therapies, tazemetostat, and sequencing changes. In the video series, Batlevi discussed the following: · Current Treatment Options and Considerations for Relapsed/Refractory Follicular Lymphoma · Third-Line Therapies in R/R FL · Use of Tazemetostat in R/R FL · Sequencing Changes in R/R FL Therapies To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.

This week, CancerNetwork spoke with Debra Patt, MD, PhD, MBA, FASCO, Executive Vice President at Texas Oncology. Patt discussed the rise of telehealth during the COVID-19 pandemic, how clinicians can use these tools to help treat patients with cancer, and the role of telemedicine moving forward.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

As part of CancerNetwork’s Between the Lines video series, Brian Helfand, MD, PhD, Chief of the Division of Urology and the Ronald L. Chez Family and Richard Melman Family Endowed Chair at NorthShore University HealthSystem, and Steven Finkelstein, MD, FACRO, a radiation oncologist with Florida Cancer Affiliates US Oncology Network in Panama City, Florida, examined the results and clinical implications of the phase 2/3 EMPIRE-1 trial in prostate cancer. The trial compares 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy. To watch more videos in CancerNetwork’s Between the Lines series, visit cancernetwork.com.

This episode features an examination of an article from the September issue of the journal ONCOLOGY, titled “Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification.” CancerNetwork spoke with one of the authors of this research, Jun Gong, MD, a practicing medical oncologist with an emphasis in GU cancers at Cedars-Sinai Medical Center.Gong detailed PSA’s role in prostate cancer, and other potential complementary biomarkers. He also discussed some of the significant findings from his research on plasma glutamine, which featured a cohort of over 100 patients with localized prostate cancer.Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork spoke with Josh Ludwig, Global Director of Commercial Operations at ScaleReady, about how this joint venture between industry leaders launched in January, is uniquely positioned to make cell and gene therapy practical and viable. Ludwig elaborated on how ScaleReady can support the entire industry, now and into the future, with a manufacturing platform that delivers a high throughput and efficient use of space. He also discussed G-Rex closed-system bioreactors, important processes for successful commercialization of cell and gene therapy, and what’s next for ScaleReady. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

CancerNetwork spoke with Quita Highsmith, Vice President and Chief Diversity Officer for Genentech, and Monica Baskin, PhD, a professor of preventive medicine and associate director for Community Outreach and Engagement for the O’Neal Comprehensive Cancer Center in Birmingham, Alabama. The conversation focused on the Advancing Inclusive Research Site Alliance, which is a coalition of clinical research sites partnering with Genentech to advance representation of diverse patient populations in oncology clinical trials. Results from clinical trials without diverse patient cohorts are rarely generalizable to the entire population, and this initiative works to educate and inform the clinicians and researchers to ultimately make clinical trials more accessible and eliminate these disparities. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

For the final installment of a 3-part relapsed/refractory DLBCL series, CancerNetwork heard from Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, and Kami Maddocks, MD, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University Wexner Medical Center. These lymphoma experts spoke about their thoughts on data from the L-MIND trial, when to implement CAR-T cell therapies for patients, the role of Selinexor in treating patients, and a host of other important ideas. Don’t forget to subscribe to the Oncology Peer Review On-The-Go podcast on Apple Podcasts, Spotify or anywhere podcasts are available. Be sure to check out the 2 other installments of this 3-part DLBCL series on rituximab rechallenging and different treatment regimens.